[6-K] Jyong Biotech Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Jyong Biotech Ltd. appointed Wei (Vivi) Zhang as its new Chief Financial Officer, effective February 6, 2026, replacing former CFO Alfred Ying. The change places an experienced capital markets and public-company finance executive in charge of the company’s financial leadership.

Ms. Zhang has led initial public offerings, fundraising activities and finance functions for listed companies. She previously served as Chief Financial Officer and director at Global Mofy AI Limited from 2019 to January 2024 and holds an accounting degree from the University of South Australia and an MBA from the University of Oxford.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-42701

Jyong Biotech Ltd.

23F-3, No. 95, Section 1, Xintai 5^th Road,
Xizhi District, New Taipei City,
Taiwan, 221

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On February 6, 2026, Jyong Biotech Ltd. (the “Company”) announced that Wei (Vivi) Zhang has been appointed as the Company’s Chief Financial Officer, effective February 6, 2026. Ms. Zhang will be replacing Alfred Ying.

Ms. Wei (Vivi) Zhang is an experienced finance executive with extensive leadership experience in initial public offerings, funds raising and public companies. Most recently, Ms. Wei served as a consultant for a private company in its initial public offering process. Before that, from 2019 to January 2024, she served as Chief Financial Officer and director at Global Mofy AI Limited (f/k/a Global Mofy Metaverse Limited) (listed on Nasdaq since 10/2023: GMM). Ms. Zhang received a bachelor’s degree in accounting from the University of South Australia and an MBA degree from the University of Oxford.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Jyong Biotech Ltd.
Date: February 6, 2026	By:	/s/ Fu-Feng Kuo
	Name:	Fu-Feng Kuo
	Title:	Chief Executive Officer

2

FAQ

Who is the new CFO of Jyong Biotech Ltd. (MENS)?

Jyong Biotech Ltd. appointed Wei (Vivi) Zhang as Chief Financial Officer effective February 6, 2026. She brings extensive experience in initial public offerings, fundraising and managing finance for public companies, including prior service as CFO and director at Global Mofy AI Limited.

When did Jyong Biotech (MENS) announce its new CFO appointment?

Jyong Biotech Ltd. announced the appointment of Wei (Vivi) Zhang as Chief Financial Officer on February 6, 2026. Her appointment is effective the same day, marking an immediate transition in the company’s senior financial leadership from former CFO Alfred Ying.

What is the professional background of Jyong Biotech’s new CFO?

Wei (Vivi) Zhang is an experienced finance executive with extensive leadership in IPOs, fundraising and public-company finance. She most recently consulted on a private company’s IPO process and previously served as Chief Financial Officer and director at Global Mofy AI Limited from 2019 to January 2024.

Which executive is Jyong Biotech’s new CFO replacing?

Jyong Biotech Ltd.’s new Chief Financial Officer, Wei (Vivi) Zhang, is replacing Alfred Ying. The filing states that her appointment is effective February 6, 2026, indicating a direct handover of the company’s CFO responsibilities to Ms. Zhang on that date.

What education does Jyong Biotech’s new CFO, Wei Zhang, have?

Wei (Vivi) Zhang holds a bachelor’s degree in accounting from the University of South Australia and an MBA degree from the University of Oxford. This combination of accounting and advanced business training supports her role overseeing Jyong Biotech Ltd.’s financial reporting and capital markets activities.